Cochlear Limited
Cochlear Limited
Your view on COH.AX
Overview
What the company does, where it operates, and who runs it.
About Cochlear Limited
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Diggory William Howitt
- Headquarters
- 1 University Avenue, Sydney, NSW, AU
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Diggory William Howitt
- Headquarters
- 1 University Avenue, Sydney, NSW, AU
Globally, Cochlear Limited specializes in the development and provision of implantable auditory solutions for both children and adults. The company's diverse offerings include advanced cochlear implant systems, upgrades for sound processors, bone conduction devices, and a wide array of accessories and other related items. Established in 1981, its global operations are directed from its headquarters in Sydney, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Cochlear Limited, and the rating behind it. COH.AX last traded at AUD 124.86, 29.8× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Cochlear Limited. Starting points for Cochlear Limited: P/E 29.8, EPS AUD 4.54, beta 0.26 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Cochlear Limited. Cochlear Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Cochlear Limited. Trailing twelve-month EPS for Cochlear Limited stands at AUD 4.54. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Cochlear Limited. Cochlear Limited has reported as a listed company since 1995. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Cochlear Limited valued side by side against its closest peers. Cochlear Limited is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Cochlear Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Cochlear Limited executives and directors. Shares of Cochlear Limited have traded between AUD 88.74 and AUD 314.61 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Cochlear Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Cochlear Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Cochlear Limited. Coverage tracks Cochlear Limited within Medical - Devices (Healthcare). Press releases and market coverage, newest first.